Justin Ranes, MD
Pulmonary Disease · Kansas City, MONPI 1932182532
Payments from drug & device makers
Across 242 payments — averaging $33.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- AstraZeneca$590
- GSK$586
- Boehringer Ingelheim$318
- AbbVie$282
- Jazz Pharmaceuticals Inc.$222
- plus $2K from 30 others
What the payments were for
- Travel & lodging$1,01912%
- Food & beverage$4,16651%
- Education$3,02637%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $4,019 |
| AstraZeneca | 36 | $590 |
| GSK | 33 | $586 |
| Boehringer Ingelheim | 16 | $318 |
| AbbVie(2 entities) | 10 | $282 |
| Jazz Pharmaceuticals Inc. | 12 | $222 |
| Sanofi | 10 | $202 |
| Electromed, Inc. | 12 | $160 |
| Merck | 9 | $153 |
| Harmony Biosciences LLC | 7 | $141 |
| Mylan Specialty L.p. | 8 | $132 |
| Insmed, Inc. | 7 | $131 |
| Grifols USA, LLC | 6 | $124 |
| Genentech USA, Inc. | 8 | $122 |
| United Therapeutics Corporation | 6 | $114 |
| Sunovion Pharmaceuticals Inc. | 11 | $103 |
| Axsome Therapeutics, Inc. | 4 | $99 |
| Advanced Respiratory, Inc | 5 | $95 |
| Regeneron Healthcare Solutions, Inc. | 4 | $88 |
| Novartis | 4 | $74 |
| Amgen | 4 | $70 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Teva Pharmaceuticals USA, Inc. | 3 | $40 |
| Baxter Healthcare | 2 | $37 |
| Philips North America LLC | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| Optinose US, Inc. | 1 | $28 |
| ZOLL Respicardia, Inc. | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $25 |
| Circassia Inc. | 2 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $21 |
| Verona Pharma, Inc. | 1 | $21 |
| Pulmonx Corporation | 1 | $18 |
| Johnson & Johnson | 1 | $16 |
| Shire North American Group Inc | 1 | $11 |
| Veran Medical Technologies, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$3,981
How this compares
$8,211 in reported general payments places this provider in the 65th percentile of 295 pulmonary disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 259 | $233,960 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 135 | $102,981 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 131 | $76,609 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 99 | $73,237 |
| Breo ElliptaFluticasone/Vilanterol | 134 | $70,989 |
| Spiriva RespimatTiotropium Bromide | 103 | $70,294 |
| Dupixent SyringeDupilumab | 11 | $48,423 |
| SymbicortBudesonide/Formoterol Fumarate | 78 | $28,139 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 97 | $16,213 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 34 | $14,570 |
| Arnuity ElliptaFluticasone Furoate | 41 | $14,102 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 45 | $12,838 |
| EliquisApixaban | 15 | $12,640 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $10,073 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 271 | $8,599 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $586 | $405,733587 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $318 | $148,833213 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $590 | $145,690247 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 295 pulmonary disease providers in Missouri.
Other pulmonary disease in Kansas City
- Mark YaganKansas City$162K
- Timothy SmithKansas City$107K
- Matthew AboudaraKansas City$30K
- Andrea CoveyKansas City$23K
- Steven HullLees Summit$10.1M
- Thomas SilerSaint Charles$5.5M
- Neil EttingerChesterfield$3.5M
- Humam FarahHannibal$2.7M
- Murali ChakinalaSaint Louis$2.4M
- Joseph OjileSaint Louis$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.